Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Alice Tsang Shaw, Se-Hoon Lee, Suresh S. Ramalingam, Todd Michael Bauer, Michael J. Boyer, Enric Carcereny Costa, Enriqueta Felip, Ji-Youn Han, Toyoaki Hida, Brett Gordon Maxwell Hughes, Sang-We Kim, Makoto Nishio, Takashi Seto, Patrick Ezeh, Debasis Chakrabarti, Jing Wang, Andrew Chang, Luca Fumagalli, Benjamin J. Solomon
Institutions: Massachusetts General Hospital, Samsung Medical Center, Emory University, Winship Cancer Institute, Tennessee Oncology, Chris O’Brien Lifehouse, Institut Català d'Oncologia, Vall d'Hebron Hospital Universitari, National Cancer Center, National Cancer Center Hospital, Aichi Cancer Center, Prince Charles Hospital, Asan Medical Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, National Hospital Organization Kyushu Cancer Center, Pfizer (United States), Peter MacCallum Cancer Centre
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891004049